Qiang Wang Selected Research

physcione

2/2021	Retraction notice to "physcion 8-O-β-glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis" [Biomed. Pharmacother. 104 (2018) 28-35].
1/2021	Retraction Notice to "Physcion 8-O-β-glucopyranoside induces apoptosis, suppresses invasion and inhibits epithelial to mesenchymal transition of hepatocellular carcinoma HepG2 cells of hepatocellular carcinoma HepG2 cells" [Biomedicine & Pharmacotherapy 83 (2016) 372-380].
1/2018	RETRACTED: Physcion 8-O-β-glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis.
10/2016	Physcion 8-O-β-glucopyranoside induces apoptosis, suppresses invasion and inhibits epithelial to mesenchymal transition of hepatocellular carcinoma HepG2 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qiang Wang Research Topics

Disease

324	Neoplasms (Cancer) 12/2022 - 01/2002
66	Infections 07/2022 - 07/2004
62	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2002
62	Inflammation (Inflammations) 07/2022 - 03/2006
44	Schizophrenia (Dementia Praecox) 01/2022 - 08/2004
39	Infarction (Infarctions) 01/2022 - 01/2003
39	Brain Ischemia (Cerebral Ischemia) 01/2022 - 12/2003
35	Colorectal Neoplasms (Colorectal Cancer) 12/2022 - 11/2004
35	Breast Neoplasms (Breast Cancer) 05/2022 - 06/2009
34	Carcinogenesis 12/2022 - 12/2005
34	Stomach Neoplasms (Stomach Cancer) 06/2022 - 01/2002
34	Carcinoma (Carcinomatosis) 10/2021 - 08/2005
33	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 07/2003
29	COVID-19 04/2022 - 01/2020
29	Reperfusion Injury 01/2021 - 12/2003
28	Wounds and Injuries (Trauma) 10/2022 - 02/2006
28	Ischemia 02/2022 - 06/2005
26	Stroke (Strokes) 01/2022 - 01/2009
25	Fibrosis (Cirrhosis) 01/2022 - 01/2004
24	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2010
23	Body Weight (Weight, Body) 05/2021 - 03/2010
22	Hypoxia (Hypoxemia) 02/2022 - 06/2010
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2013
20	Pain (Aches) 03/2022 - 06/2010
19	Necrosis 05/2022 - 10/2011
18	Myocardial Infarction 01/2022 - 06/2009
17	Glioma (Gliomas) 08/2022 - 01/2013
17	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 01/2008
16	Lung Injury 04/2022 - 09/2002
16	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2010
15	Sepsis (Septicemia) 02/2022 - 02/2009
15	Parkinson Disease (Parkinson's Disease) 01/2022 - 10/2014
14	Mitochondrial Diseases (Mitochondrial Disease) 11/2022 - 08/2015
14	Cognitive Dysfunction 11/2022 - 08/2010
13	Osteosarcoma (Osteogenic Sarcoma) 03/2022 - 01/2013
13	Obesity 01/2022 - 09/2012
13	Rheumatoid Arthritis 01/2022 - 12/2010
13	Melanoma (Melanoma, Malignant) 01/2022 - 03/2017
13	Asthma (Bronchial Asthma) 01/2022 - 11/2008
13	Atherosclerosis 01/2022 - 10/2006
12	Insulin Resistance 02/2022 - 01/2013
12	Lymphatic Metastasis 12/2021 - 09/2008
12	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2021 - 01/2003
12	Hypertension (High Blood Pressure) 03/2021 - 09/2012
11	Ovarian Neoplasms (Ovarian Cancer) 05/2022 - 02/2012
11	Myocardial Ischemia (Ischemic Heart Diseases) 02/2022 - 10/2010
11	Colonic Neoplasms (Colon Cancer) 01/2022 - 01/2002
10	Osteoporosis 04/2022 - 05/2014
10	Pneumonia (Pneumonitis) 02/2022 - 07/2006
10	Type 2 Diabetes Mellitus (MODY) 02/2022 - 02/2014

Drug/Important Bio-Agent (IBA)

134	Proteins (Proteins, Gene)FDA Link 07/2022 - 07/2004
103	Biomarkers (Surrogate Marker)IBA 05/2022 - 08/2009
61	Messenger RNA (mRNA)IBA 04/2022 - 07/2003
59	Pharmaceutical PreparationsIBA 05/2022 - 04/2002
53	MicroRNAs (MicroRNA)IBA 07/2022 - 02/2008
51	CytokinesIBA 07/2022 - 07/2004
45	Long Noncoding RNAIBA 12/2022 - 01/2014
44	Biological ProductsIBA 07/2022 - 02/2006
31	RNA (Ribonucleic Acid)IBA 07/2022 - 01/2014
23	Small Interfering RNA (siRNA)IBA 05/2022 - 06/2009
23	Phosphotransferases (Kinase)IBA 05/2022 - 11/2004
23	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 04/2011
22	Therapeutic UsesIBA 05/2022 - 08/2005
22	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2009
21	salicylhydroxamic acid (SHAM)IBA 01/2022 - 12/2003
21	EnzymesIBA 10/2021 - 08/2007
18	Transcription Factors (Transcription Factor)IBA 01/2022 - 05/2009
18	Neuroprotective AgentsIBA 11/2021 - 10/2005
17	LipidsIBA 01/2022 - 03/2010
17	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 01/2007
17	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 03/2006
16	Interleukin-6 (Interleukin 6)IBA 01/2022 - 06/2010
15	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2022 - 07/2004
15	LigandsIBA 01/2022 - 10/2012
14	CollagenIBA 07/2022 - 05/2014
14	CalciumIBA 05/2022 - 06/2010
14	CholesterolIBA 01/2022 - 01/2012
14	HMGB1 Protein (HMG1)IBA 01/2022 - 07/2004
14	Adenosine Triphosphate (ATP)IBA 12/2021 - 06/2010
13	CateninsIBA 05/2022 - 01/2016
12	Peptides (Polypeptides)IBA 01/2022 - 06/2009
12	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2014
11	AntioxidantsIBA 12/2022 - 08/2009
11	NitrogenIBA 07/2022 - 01/2013
11	CarbonIBA 07/2022 - 05/2014
11	Caspase 3 (Caspase-3)IBA 05/2022 - 06/2008
11	Antiviral Agents (Antivirals)IBA 01/2022 - 02/2013
11	Oxygen (Dioxygen)IBA 01/2022 - 07/2008
11	DNA (Deoxyribonucleic Acid)IBA 03/2020 - 01/2009
10	Indicators and Reagents (Reagents)IBA 12/2022 - 09/2016
10	Serotonin (5 Hydroxytryptamine)IBA 10/2022 - 02/2007
10	LipopolysaccharidesIBA 09/2022 - 02/2009

Therapy/Procedure

127	Therapeutics 08/2022 - 01/2002
45	Drug Therapy (Chemotherapy) 07/2022 - 04/2007
32	Electroacupuncture 11/2021 - 01/2003
25	Radiotherapy 01/2022 - 07/2005
17	Immunotherapy 07/2022 - 05/2009
16	Transplantation 02/2021 - 08/2006
11	Ligation 02/2022 - 12/2003
11	Acupuncture Points (Acupuncture Point) 01/2022 - 01/2003